https://www.zacks.com/stock/news/2245062/pharma-stock-roundup-azn-to-buy-fusn-pfe-to-sell-stake-in-hln-other-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2245062
Mar 22, 2024 - AstraZeneca (AZN) is set to acquire Fusion Therapeutics (FUSN). Pfizer (PFE) plans to sell some shares of Haleon to lower stake from 32% to 24%.
zc:-3776330917213329406
0
https://www.zacks.com/stock/news/2242895/johnson-johnson-jnj-nvidia-unite-to-boost-ai-for-surgery?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242895
Mar 19, 2024 - Johnson & Johnson (JNJ) collaborates with Nvidia to facilitate the creation of AI-based models and the deployment of applications, offering a route to scale within its digital ecosystem for surgery.
zc:-1580039007392818244
0
https://www.zacks.com/stock/news/2242442/johnson-johnson-jnj-stock-dips-while-market-gains-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2242442
Mar 18, 2024 - Johnson & Johnson (JNJ) closed the most recent trading day at $156.76, moving -0.9% from the previous trading session.
zc:-8487695140326696076
0
https://www.zacks.com/stock/news/2242244/bristol-myers-bmy-abecma-gets-odac-votes-for-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242244
Mar 18, 2024 - Bristol Myers' (BMY) Abecma gets eight out of 11 votes from the FDA's ODAC for patients with triple-class exposed relapsed or refractory multiple myeloma in earlier lines of therapy.
zc:-85513231562097745
0
https://www.fool.com/investing/2024/03/16/magnificent-seven-stock-pays-most-dividends/?source=iedfolrf0000001
Mar 16, 2024 - Microsoft is the complete package.
0
fool:-5058767896321207201
0
https://www.zacks.com/stock/news/2241296/pharma-stock-roundup-azn-s-new-acquisition-fda-updates-for-nvo-lly-and-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2241296
Mar 15, 2024 - AstraZeneca (AZN) is set to buy a private rare disease drugmaker. FDA delays decision on Lilly's (LLY) donanemab and approves Novo Nordisk's (NVO) Wegovy for reducing cardiovascular risks.
zc:-4303199437016293624
0
https://www.zacks.com/stock/news/2241446/bristol-myers-bmy-gets-fda-nod-for-breyanzi-s-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241446
Mar 15, 2024 - Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
zc:-3282508303580057856
0
https://www.zacks.com/commentary/2240062/top-stock-reports-for-unitedhealth-johnson-johnson-oracle?cid=CS-ZC-FT-research_daily-2240062
Mar 13, 2024 - Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Johnson & Johnson (JNJ) and Oracle Corporation (ORCL).
zc:-1350128636118921996
0
https://www.zacks.com/stock/news/2238322/pharma-stock-roundup-nvo-s-new-obesity-pill-data-rhhby-azn-s-pipeline-updates?cid=CS-ZC-FT-analyst_blog|stock_roundup-2238322
Mar 08, 2024 - Novo Nordisk???s (NVO) early-stage data on a new weight loss pill, amycretin, shows it can outperform Wegovy. FDA approves J&J???s (JNJ) Rybrevant for first-line use.
zc:8954737857558499476
0
https://www.zacks.com/stock/news/2236717/bayer-bayry-q4-earnings-top-crop-science-unit-drives-revenues?cid=CS-ZC-FT-analyst_blog|earnings_article-2236717
Mar 06, 2024 - Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased sales of Crop Science and Pharmaceuticals products.
zc:4521125375410249720
0